ReviewAnnals of surgical oncology2026
BRCA Mutation Carriers and Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Accumulating Evidence, Proposed Mechanism, and Implications for Reconstructive Planning and Follow-Up.
Review in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is an uncommon cluster of differentiation (CD)-30-positive T-cell lymphoma arising in the peri-implant capsule that was recognized as a definitive entity by the World Health Organization (WHO) in its 2022 fifth edition. Although historically framed as a device complication of textured implant surfaces, recent evidence suggests that germline mutations in BRCA1, BRCA2, and TP53 confer independent host-level susceptibility. These findings have yet to be synthesized for the surgical oncology audience.
methodsThis was a narrative review adhering to Scale for the Assessment of Narrative Review Articles (SANRA) criteria. PubMed and MEDLINE were searched from January 2000 through March 2026. Evidence was ranked using the 2011 Oxford Centre for Evidence-Based Medicine levels of evidence. DISCUSSION: Four evidence streams spanning 15 years have consistently associated germline BRCA1/2 and TP53 mutations with elevated BIA-ALCL risk. The 2025 Memorial Sloan Kettering Cancer Center prospective cohort reported a 16-fold increased age-adjusted risk in BRCA1/2 carriers (95% confidence interval 3.6-76.1). Compressed disease latency has been observed in mutation carriers. Overall, these reports suggest a gene-environment interaction model where impaired homologous recombination repair lowers the threshold for clonal T-lymphocyte expansion in the chronic inflammatory peri-implant microenvironment. Autologous reconstruction eliminates the BIA-ALCL risk. Thus, both autologous and smooth implant-based reconstruction should be explicitly discussed with BRCA carriers, and textured devices should be avoided if implant-based reconstruction is chosen. Surveillance strategies, including explicit documentation, earlier investigation thresholds, and structured long-term handoff, are recommended.
conclusionsThe evidence is observational and not yet sufficient for prescriptive guidelines but is consistent, biologically coherent, and of sufficient magnitude to warrant a measured adjustment in reconstructive counseling, implant selection, and follow-up in BRCA mutation carriers.
Indexed as
Identifiers
42848302What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.